Q3 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Novartis pipeline in Phase 1 Oncology Code Name Solid tumors AAA603 177Lu-NeoB AAA614 AAA614 AAA817 DFF332 DFF332 HRO761 HRO761 IAG933 IAG933 KFA115 KFA115 MGY825 MGY825 NZV930 NZV930 QEQ278 QEQ278 225AC-PSMA-617 Hematology DFV890 DFV890 sabatolimab PIT565 MBG453 PIT565 YTB323 Mechanism Radioligand therapy target GRPR Radioligand therapy target FAP Radioligand therapy target PSMA HIF2A inhibitor Werner inhibitor Novel immunomodulatory Agent CD73 antagonist NKG2D/-L pathway modulator NLRP3 inhibitor TIM3 antagonist rapcabtagene autoleucel CD19 CAR-T Indication(s) Multiple solid tumors Breast cancer Solid tumors Metastatic castration-resistant prostate cancer Renal cell carcinoma Solid tumors Mesothelioma Solid tumors NSCLC Solid tumors Solid tumors Low risk myelodysplastic syndrome Low risk myelodysplastic syndrome B-cell malignancies Adult ALL Neuroscience Code Name DFT383 DFT383 NIO752 NIO752 Mechanism CTNS gene delivery Tau antisense oligonucleotide Indication(s) Cystinosis pre/post kidney transplant Alzheimer's disease Progressive supranuclear palsy Cardiovascular Code Name XXB750 XXB750 Mechanism NPR1 agonist 34 Investor Relations | Q3 2023 Results Indication(s) Heart failure Conclusions Appendix Innovation: Clinical trials Immunology References Abbreviations INNOVATION 16 lead indications Code Name MHV370 MHV370 Mechanism TLR7, TLR8 Antagonist Indication(s) Systemic lupus erythematosus Others Name Mechanism Code IB&GH EDI048 EDI048 EYU688 EYU688 INE963 INE963 CpPI(4)K inhibitor NS4B inhibitor Indication(s) Cryptosporidiosis Dengue Malaria, uncomplicated Lead indication NOVARTIS | Reimagining Medicine

View entire presentation